TR199800990T2 - Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler. - Google Patents

Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.

Info

Publication number
TR199800990T2
TR199800990T2 TR1998/00990T TR9800990T TR199800990T2 TR 199800990 T2 TR199800990 T2 TR 199800990T2 TR 1998/00990 T TR1998/00990 T TR 1998/00990T TR 9800990 T TR9800990 T TR 9800990T TR 199800990 T2 TR199800990 T2 TR 199800990T2
Authority
TR
Turkey
Prior art keywords
methods
intermediates
compositions containing
manufacture
pharmaceutical
Prior art date
Application number
TR1998/00990T
Other languages
English (en)
Turkish (tr)
Inventor
E.Zook Scott
Jr. Dagnino Raymond
E.Deason Michael
L.Bender Steven
J.Melnick Michael
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of TR199800990T2 publication Critical patent/TR199800990T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TR1998/00990T 1995-12-08 1996-12-05 Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler. TR199800990T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56976695A 1995-12-08 1995-12-08

Publications (1)

Publication Number Publication Date
TR199800990T2 true TR199800990T2 (xx) 1998-07-21

Family

ID=24276764

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00990T TR199800990T2 (xx) 1995-12-08 1996-12-05 Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.

Country Status (39)

Country Link
US (1) US6153757A (enExample)
EP (2) EP1095936B1 (enExample)
JP (1) JP2000502330A (enExample)
KR (1) KR19990072009A (enExample)
CN (2) CN1207289C (enExample)
AP (2) AP1368A (enExample)
AT (2) ATE234291T1 (enExample)
AU (1) AU725831C (enExample)
BG (1) BG64279B1 (enExample)
BR (1) BR9611929A (enExample)
CA (1) CA2238306A1 (enExample)
CO (1) CO4790150A1 (enExample)
CZ (1) CZ292942B6 (enExample)
DE (2) DE69626684T2 (enExample)
DK (1) DK0874830T3 (enExample)
EA (1) EA003294B1 (enExample)
ES (2) ES2233275T3 (enExample)
GE (1) GEP20012388B (enExample)
GT (2) GT199700015A (enExample)
HR (1) HRP970031A2 (enExample)
HU (1) HUP9902092A3 (enExample)
ID (1) ID17624A (enExample)
IL (6) IL138027A (enExample)
MX (1) MX9804457A (enExample)
MY (1) MY117290A (enExample)
NO (1) NO311360B1 (enExample)
NZ (1) NZ325559A (enExample)
OA (1) OA10794A (enExample)
PA (1) PA8431301A1 (enExample)
PE (1) PE69298A1 (enExample)
PL (1) PL327275A1 (enExample)
PT (1) PT874830E (enExample)
SI (1) SI0874830T1 (enExample)
SK (1) SK73898A3 (enExample)
SV (1) SV1997000008A (enExample)
TR (1) TR199800990T2 (enExample)
TW (1) TW546293B (enExample)
WO (1) WO1997020824A1 (enExample)
YU (1) YU21597A (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) * 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
EA003294B1 (ru) * 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
ATE233552T1 (de) * 1996-07-22 2003-03-15 Monsanto Co Thiol-sulfonen als metalloproteinaseinhibitoren
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
HUP0000505A3 (en) * 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
US6872742B2 (en) 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
BR9713465A (pt) * 1996-08-28 2000-03-28 Procter & Gamble Inibidores metalotprotease de amina cìclica sibstituìda
CN1228771A (zh) * 1996-08-28 1999-09-15 普罗克特和甘保尔公司 1,3－二杂环金属蛋白酶抑制剂
ATE226573T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Heterozyklische metalloproteaseinhibitoren
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
KR20000049197A (ko) * 1996-10-16 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 및 종양 괴사 인자-α 전환 효소억제제로서의 오르토-설폰아미도 헤테로아릴 하이드록삼산의 제조 및 용도
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
IL131493A (en) 1997-03-04 2004-05-12 Monsanto Co Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6087359A (en) * 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
EP0983267B1 (en) * 1997-03-04 2005-01-26 Pharmacia Corporation Amidoaromatic ring sulfonamide hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0973748A1 (en) * 1997-04-01 2000-01-26 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
CN1265647A (zh) 1997-07-31 2000-09-06 普罗克特和甘保尔公司 无环金属蛋白酶抑制剂
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
JPH11199512A (ja) * 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
JP2001523662A (ja) 1997-11-14 2001-11-27 ジー・ディー・サール・アンド・カンパニー 芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
CN1293663A (zh) * 1998-01-27 2001-05-02 美国氰胺公司 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
PL342009A1 (en) 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
BR9910678A (pt) 1998-05-14 2001-10-02 Du Pont Pharm Co Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
WO1999065867A1 (en) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
EP1357109B1 (en) 1998-06-18 2008-07-23 F. Hoffmann-La Roche Ag Process for aryl alkyl sulfide
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
WO2000009492A1 (en) * 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
JP2002525305A (ja) * 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー スルホンアミドを用いた脱毛治療の方法
US6288261B1 (en) * 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AU775701B2 (en) 1999-02-08 2004-08-12 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
SK12462001A3 (sk) 1999-03-03 2002-04-04 The Procter & Gamble Company Inhibítory metaloproteáz
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
ATE260272T1 (de) * 2000-03-17 2004-03-15 Bristol Myers Squibb Pharma Co Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
US6548667B2 (en) * 2000-04-07 2003-04-15 Samsung Electronics Co. Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US6927216B2 (en) 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6642255B2 (en) 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
WO2002055516A2 (en) 2001-01-11 2002-07-18 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a)
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
EP1373199A4 (en) 2001-03-15 2004-04-07 Bristol Myers Squibb Pharma Co SPIROCYCLIC BETA-AMINOACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND THE CONVERSION ENZYME OF TNF-ALPHA (TAGE)
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
JP2004530691A (ja) 2001-05-11 2004-10-07 ファルマシア・コーポレーション 芳香族スルホンヒドロキサメートおよびプロテアーゼ阻害剤としてのそれらの使用
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
WO2003048119A2 (en) * 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Method of producing n-[(2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003233154A1 (en) * 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
AU2003237532B2 (en) * 2002-06-12 2009-07-30 Symphony Evolution, Inc. Human ADAM-10 inhibitors
US20040167182A1 (en) * 2002-06-25 2004-08-26 Becker Daniel P. Hydroxamic acid and amide compounds and their use as protease inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
WO2004071390A2 (en) * 2003-02-14 2004-08-26 Applied Research Systems Ars Holding N.V. Piperazine-2-carboxamide derivatives
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
ZA200507806B (en) 2003-03-24 2007-03-28 Actimis Pharmaceuticals Inc 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
GT200500139A (es) 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
WO2009052200A2 (en) * 2007-10-16 2009-04-23 Symphony Evolution, Inc. Human adam-10 inhibitors
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2011081884A1 (en) 2009-12-14 2011-07-07 Massachusetts Institute Of Technology Systems and methods related to optical nanosensors including photoluminescent nanostructures
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
CN103998435A (zh) * 2011-10-04 2014-08-20 法国国家健康医疗研究院 新型细胞凋亡诱导化合物
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
KR102890026B1 (ko) * 2019-04-26 2025-11-24 닛산 가가쿠 가부시키가이샤 아릴술폰산 에스테르 화합물의 제조 방법
WO2020252439A1 (en) * 2019-06-14 2020-12-17 Loyola University Of Chicago Carborane hydroxamic acid matrix metalloproteinase agents for boron neutron capture therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
JPH05503719A (ja) * 1990-12-03 1993-06-17 セルテック　リミテッド ペプチジル誘導体
WO1992021360A1 (en) * 1991-05-28 1992-12-10 Merck & Co., Inc. Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5672583A (en) * 1992-11-25 1997-09-30 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
NZ271765A (en) * 1993-08-05 1996-11-26 Syntex Inc Bridged [1,3]indolo macrocyclic lactam compounds and pharmaceutical compositions
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
AU678884B2 (en) * 1994-01-22 1997-06-12 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
ATE181055T1 (de) * 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
AU690703B2 (en) * 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
ES2185750T3 (es) * 1995-08-08 2003-05-01 Ono Pharmaceutical Co Derivados de acido hidroxamico utiles para la inhibicion gelatinasa.
TR199800849T2 (xx) * 1995-11-13 1998-07-21 Hoechst Aktiengesellschaft Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
EA003294B1 (ru) * 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
NZ323329A (en) * 1995-12-22 1999-02-25 Warner Lambert Co 4-phenyl-piperidin-1-yl butyric acid derivatives and medicaments
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
EP0922030A1 (en) * 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
BR9713465A (pt) * 1996-08-28 2000-03-28 Procter & Gamble Inibidores metalotprotease de amina cìclica sibstituìda
HUP0000505A3 (en) * 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
CN1207734A (zh) 1999-02-10
TW546293B (en) 2003-08-11
AP2001002270A0 (en) 2001-09-30
CZ173398A3 (cs) 1998-11-11
BG102510A (en) 1999-08-31
MY117290A (en) 2004-06-30
IL138027A (en) 2004-08-31
NZ325559A (en) 2000-01-28
SI0874830T1 (en) 2003-08-31
IL124559A0 (en) 1998-12-06
HUP9902092A2 (hu) 1999-09-28
CN1542002A (zh) 2004-11-03
NO982590D0 (no) 1998-06-05
ES2233275T3 (es) 2005-06-16
GT199700015A (es) 1998-07-23
ID17624A (id) 1998-01-15
IL134816A (en) 2003-02-12
SV1997000008A (es) 1999-02-15
ATE283264T1 (de) 2004-12-15
IL134816A0 (en) 2001-05-20
CA2238306A1 (en) 1997-06-12
SK73898A3 (en) 1999-01-11
DE69633947D1 (de) 2004-12-30
AU725831B2 (en) 2000-10-19
CZ292942B6 (cs) 2004-01-14
GEP20012388B (en) 2001-03-25
US6153757A (en) 2000-11-28
IL138028A0 (en) 2001-10-31
HUP9902092A3 (en) 2000-12-28
WO1997020824A1 (en) 1997-06-12
EP0874830A1 (en) 1998-11-04
CO4790150A1 (es) 1999-05-31
YU21597A (en) 1999-11-22
PL327275A1 (en) 1998-12-07
JP2000502330A (ja) 2000-02-29
MX9804457A (es) 1998-09-30
BG64279B1 (bg) 2004-08-31
DE69626684D1 (de) 2003-04-17
AP1368A (en) 2005-04-21
KR19990072009A (ko) 1999-09-27
NO311360B1 (no) 2001-11-19
PA8431301A1 (es) 2000-05-24
IL124559A (en) 2004-07-25
NO982590L (no) 1998-08-05
HRP970031A2 (en) 1998-08-31
AP1288A (en) 2004-07-21
AP9801284A0 (en) 1998-09-30
AU1409197A (en) 1997-06-27
CN1207289C (zh) 2005-06-22
DE69633947T2 (de) 2005-12-01
GT199700015AA (es) 1998-07-23
ES2195034T3 (es) 2003-12-01
DK0874830T3 (da) 2003-04-22
ATE234291T1 (de) 2003-03-15
DE69626684T2 (de) 2004-04-29
EP1095936B1 (en) 2004-11-24
EP0874830B1 (en) 2003-03-12
PT874830E (pt) 2003-06-30
PE69298A1 (es) 1998-11-13
IL138027A0 (en) 2001-10-31
AU725831C (en) 2002-10-17
EP1095936A1 (en) 2001-05-02
OA10794A (en) 2001-07-05
EA003294B1 (ru) 2003-04-24
BR9611929A (pt) 1999-05-18
EA199800541A1 (ru) 1998-12-24
IL143674A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
NO308130B1 (no) Arylsylfonamidosubstituerte hydroksaminsyrer som matriksmetalloproteinasehemmere samt anvendelse av samme for fremstilling av medikament
MY117290A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
NO20003018L (no) Triazinangiogenese-inhibitorer
NZ335013A (en) Compositions comprising cytosine derivatives for the treatment of cancer
TR200001279T2 (tr) Poli (ADP-riboz) polimeraz ("PARP") inhibitörleri, nevral ve kardiyovasküler doku hasarının tedavisi için yöntemler ve farmasötik bileşimler.
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
TR199900399T2 (xx) Matris metaloproteaz inhibit�rleri olarak fosfinik asit amidleri.
PT1023308E (pt) Inibidores do metabolismo nucleosidico
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
SE9203825L (sv) Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
NZ227436A (en) Cell proliferation inhibiting composition comprising a substituted styrene derivative
DE60027131D1 (de) Inhibitoren für asparagin-proteasen
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
AR001768A1 (es) Derivados de ciclolignano utiles como antineoplasicos composiciones farmaceuticas que los contienen y proceso para preparar dichos derivados
ES2101342T3 (es) Derivados de tetrazol substituidos con fosfono.